Search

Your search keyword '"Di Noto R"' showing total 152 results
Start Over Author "Di Noto R"
152 results on '"Di Noto R"'

17. The secretome signature of colon cancer cell lines

Author

Imperlini, Esther, Colavita, I, Caterino, M, Mirabelli, P, Pagnozzi, D, Del Vecchio, L, Di Noto, R, Ruoppolo, M, Orru', Stefania, Imperlini, Esther, Colavita, I, Caterino, Marianna, Mirabelli, P, Pagnozzi, D, DEL VECCHIO, Luigi, Di Noto, R, Ruoppolo, Margherita, and Orrù, S.

Subjects
Proteomics, Tandem Mass Spectrometry, Cell Line, Tumor, Blotting, Western, Colonic Neoplasms, Humans, Electrophoresis, Polyacrylamide Gel, Caco-2 Cells
Abstract

The definition of the secretome signature of a cancer cell line can be considered a potential tool to investigate tumor aggressiveness and a preclinical exploratory study required to optimize the search of cancer biomarkers. Dealing with a cell-specific secretome limits the contamination by the major components of the human serum and reduces the range of dynamic concentrations among the secreted proteins, thus favouring under-represented tissue-specific species. The aim of the present study is to characterize the secretome of two human colon carcinoma cell lines, CaCo-2 and HCT-GEO, in order to evaluate differences and similarities of two colorectal cancer model systems. In this study, we identified more than 170 protein species, 64 more expressed in the secretome of CaCo-2 cells and 54 more expressed in the secretome of HCT-GEO cells; 58 proteins were shared by the two systems. Among them, more than 50% were deemed to be secretory according to their Gene Ontology annotation and/or to their SignalP or SecretomeP scores. Such a characterization allowed corroborating the potential of a cell culture-based model in order to describe the cell-specific invasive properties and to provide a list of putative cancer biomarkers.

Published
2013

20. The protein expression pattern of CD133+ colon cancer cells indicates activation of the Wnt pathway and potential alteration of splicing mechanisms

Author

Corbo, C, Orrù, S, Gemei, M, Di Noto, R, Mirabelli, P, Imperlini, E, Ruoppolo, M, Del Vecchio, L, Salvatore, F, Corbo C, Orrù S, Gemei M, Di Noto R, Mirabelli P, Imperlini E, Ruoppolo M, Del Vecchio L, Salvatore F, Corbo, C, Orrù, S, Gemei, M, Di Noto, R, Mirabelli, P, Imperlini, E, Ruoppolo, M, Del Vecchio, L, Salvatore, F, Corbo C, Orrù S, Gemei M, Di Noto R, Mirabelli P, Imperlini E, Ruoppolo M, Del Vecchio L, and Salvatore F

Published
2011

21. Comparative proteomics of CD133+and CD133-colon cancer cells reveals activation of the Wnt pathway and a potential therapeutic role of SRp20

Author

Corbo, C, Orru', Stefania, Gemei, M, Di Noto, R, Mirabelli, P, Imperlini, Esther, Ruoppolo, M, Del Vecchio, L, Salvatore, F., Corbo, C, Orrù, S, Gemei, M, Di Noto, R, Mirabelli, P, Imperlini, E, Ruoppolo, M, Del Vecchio, L, Salvatore, F, Stefania, O, Marica, G, Rosa Di, N, Peppino, M, Esther, I, Margherita, R, Luigi Del, V, and Francesco, S

Subjects
cancer stem cells, colon cancer, proteomics, biomarkers, cancer stem cells, colon cancer, proteomics
Published
2012

24. A first comparative study on two cell colture techniques – stimulated T cells and continous lymphoblastoid cell lines – in the detection of LDL receptor residual activity versus molecular genetic analysys

Author

Romano M., Mirabelli P., D’Agostino M.N., Di Taranto M.D., Marotta G., Gentile M., Abate G., Di Noto R., Del Vecchio L., Fortunato G., RUBBA, PAOLO OSVALDO FEDERICO, Romano, M., Mirabelli, P., D’Agostino, M. N., Di Taranto, M. D., Marotta, G., Gentile, M., Abate, G., Di Noto, R., Del Vecchio, L., Rubba, PAOLO OSVALDO FEDERICO, and Fortunato, G.

Published
2010

26. Characterization of two novel cell lines, DERL-2 (CD56+/CD3+/Tcry5+) and DERL-7 (CD56+/CD3-/TCRgammadelta-),derived from a single patient with CD56+ non- Hodgkin's lymphoma

Author

DI NOTO R., CAMERA A., LUCIANO L., BARONE M., LO PARDO C., BOCCUNI P., INTRIERI M., IZZO, BARBARA, VILLA M.R., MACRI M., ROTOLI B., SACCHETTI L., SALVATORE F., DEL VECCHIO L., PANE, FABRIZIO, DI NOTO, R., Pane, Fabrizio, Camera, A., Luciano, L., Barone, M., LO PARDO, C., Boccuni, P., Intrieri, M., Izzo, Barbara, Villa, M. R., Macri, M., Rotoli, B., Sacchetti, L., Salvatore, F., and DEL VECCHIO, L.

Published
2001

27. characterisation of two novel cell lines, DERL-2 (CD56+/CD3+/TCR gammadelta+) and DERL-7 (CD56+/CD3-/TCR gammadelta-) derived from a single patient with CD56+ non Hodgkin lymphoma

Author

DI NOTO R., PANE, FABRIZIO, CAMERA A., LUCIANO L., BARONE M., LO PARDO C., BOCCUNI P., INTRIERI M., SACCHETTI L, SALVATORE F., DEL VECCHIO L., ROTOLI, BRUNO, DI NOTO, R., Pane, Fabrizio, Camera, A., Luciano, L., Barone, M., LO PARDO, C., Boccuni, P., Intrieri, M., Rotoli, Bruno, Sacchetti, L, Salvatore, F., and DEL VECCHIO, L.

Published
2001

28. Coexistence of two distinct cell populations (CD56(+)TcRgammadelta(+) and CD56(+)TcRgammadelta(-)) in a case of aggressive CD56(+) lymphoma/leukemia

Author

CAMERA, ANDREA, LUCIANO, LUIGIA, PANE, FABRIZIO, IZZO, BARBARA, SALVATORE, FRANCESCO, ROTOLI, BRUNO, Pezzullo L., Villa M.R., Boccuni P., Di Noto R., Del Vecchio L., Camera, Andrea, Pezzullo, L., Villa, M. R., Luciano, Luigia, Pane, Fabrizio, Izzo, Barbara, Boccuni, P., Di Noto, R., Del Vecchio, L., Salvatore, Francesco, and Rotoli, Bruno

Subjects
Adult, Male, Leukemia, CD3 Complex, Lymphoma, Splenic Neoplasms, T-Lymphocytes, Liver Neoplasms, Receptors, Antigen, T-Cell, gamma-delta, CD56 Antigen, Clone Cells, Immunophenotyping, Killer Cells, Natural, Cytogenetic Analysis, Disease Progression, Humans
Abstract

Large granular lymphocytes derive from two major lineages: one expressing the CD3 surface antigen (T-lymphocytes), and the other lacking this marker (NK-cells). Although developmental overlaps between natural killer cells and T-cells have been described, malignancies derived from these two cell types are considered as distinct lymphoid disorders.We report the case of a 30-year old man affected by a lymphoma/leukemia syndrome presenting with hepatosplenic lymphoma which rapidly transformed into aggressive NK-leukemia. Extensive flow cytometry studies and molecular analysis were repeated during the course of the disease, and showed an unexpected changing pattern.At diagnosis, flow cytometry analysis showed the co-existence of two cell populations, one CD56(+), CD3(+), TcRgd(+), and the other CD56(+), CD3(-) and TcRgd(-). Molecular analysis showed that the TcR genes had the same clonally rearranged pattern involving b, g and d genes in both populations. At disease relapse and during the terminal refractory phase, only CD3(-) cells were present.This is an unusual case of CD56(+) aggressive lymphoma/leukemia characterized by the clonal expansion of two phenotypically different cell populations, variably balanced during the course of the disease. The presence of the same TcR genomic rearrangement suggests the origin from a common progenitor able to differentiate along both T- and NK-pathways.

Published
2000

36. Surface proteomic analysis of differentiated versus stem-like osteosarcoma human cells

Author

Gemei, M, Corbo, C, D'Alessio, F, Di Noto, R, Vento, R, Del Vecchio, L, Gemei, M, Corbo, C, D'Alessio, F, Di Noto, R, Vento, R, and Del Vecchio, L

Abstract

Cancer stem cell characterization represents a breakthrough in cancer research. Despite evidence showing the existence and the role of cancer stem cells in osteosarcoma (OS) onset and progression, little is known about their specific surface phenotype. To address this issue, we carried out a cytometric analysis with an antibody-array comprising 245 membrane proteins comparing the stem and differentiated OS cells. As experimental model, we chose the stem-like cell line 3aminobenzamide-OS and its parental, differentiated, cell line MG63. We identified 50 differentially expressed, 23 homogeneously expressed, and 172 not expressed proteins in the two cell line models, thus defining a surface protein signature specific for each of them. Furthermore, we selected ERK1/2 (p44/42 mitogen-activated protein kinases) as a potential pathway correlated with processes that characterize tumorigenic potential and stemness of 3aminobenzamide-OS cells

Published
2013

37. CD66c is a novel marker for colorectal cancer stem cell isolation, and its silencing halts tumor growth in vivo

Author

Gemei, M, Mirabelli, P, Di Noto, R, Corbo, C, Iaccarino, A, Zamboli, A, Troncone, G, Galizia, G, Del Vecchio, L, Salvatore, F, Gemei, M, Mirabelli, P, Di Noto, R, Corbo, C, Iaccarino, A, Zamboli, A, Troncone, G, Galizia, G, Del Vecchio, L, and Salvatore, F

Abstract

BACKGROUND: Despite the well recognized expression of the cell surface markers cluster of differentiation 44 (homing cell adhesion molecule) and CD133 (Prominin 1) on human colorectal cancer stem cells (CCSCs), these molecules do not appear to be effective targets for stem cell-directed therapies. Because the surface marker CD66c (also known as carcinoembryonic antigen-related cell adhesion molecule 6) has demonstrated promise as a therapeutic target in pancreatic malignancy, the authors evaluated its potential as a target for stem cell-directed treatment of colorectal cancer. METHODS: First, the authors characterized CD66c expression by flow cytometry and immunohistochemistry in colon cancer samples and in normal colon tissues. Then, the coexpression of CD66c and CD133 was evaluated on putative CCSCs. CD66c expression also was measured in stem cell-enriched colon spheres. Finally, the effects of small-interfering RNA-mediated CD66c silencing on the in vitro and in vivo growth of Caco2 colon cancer cells were evaluated. RESULTS: CD66c expression was significantly higher in colon cancers than in contiguous normal colon tissues and paralleled cancer stage. CD66c was absent in CD133-positive cells that were isolated from normal colon, whereas its expression was brightest (CD66cbright) in CD133-positive cells from colon cancer samples. In vitro experiments demonstrated that colon spheres were considerably enriched in a CD66cbright population in a fashion comparable to the enrichment observed in fresh liver metastases. In vitro proliferation and clonogenic potential were hampered when CD66c was silenced in Caco2 cells. Finally, in vivo xenograft experiments demonstrated that CD66c silencing almost completely abrogated the tumorigenic potential of Caco2 cells. CONCLUSIONS: CD66cbright expression was associated with colon cancer stem cells and CD66c silencing blocked tumor growth, thereby opening the way to a potential new treatment for colon cancer. Cancer 2013.

Published
2013

42. Spontaneous splenic rupture in a patient with acute lymphoblastic leukemia of Burkitt type

Author

D'Ambrosio, Di Noto R, Felicetto Ferrara, Mele G, Romano L, Giovine S, Ferrara, F., D'Ambrosio, V., DI NOTO, Rosa, Mele, G., Giovine, S., and Romano, L.

Subjects
Spontaneous rupture, Adult, Male, Cancer Research, medicine.medical_specialty, medicine.medical_treatment, Lymphoblastic Leukemia, Splenectomy, Spleen, Laparotomy, Antineoplastic Combined Chemotherapy Protocols, medicine, Humans, Hemoperitoneum, Chemotherapy, Rupture, Spontaneous, business.industry, Remission Induction, Hematology, Splenic Rupture, medicine.disease, Burkitt Lymphoma, Surgery, Abdominal Pain, Leukemia, medicine.anatomical_structure, Oncology, medicine.symptom, business
Abstract

We describe a case of spontaneous splenic rupture occurred in a patient with acute lymphoblastic leukemia of Burkitt type before starting cytotoxic chemotherapy. Left hypochondrial pain radiating to the homolateral shoulder was the only clinical symptom. Emergency computed tomography showed splenic laceration and hemoperitoneum. The patient underwent immediate laparotomy with splenectomy and experienced an uneventful postoperative recovery. Eight days after surgery, chemotherapy could be administered and complete remission was achieved. Although spontaneous rupture of the spleen is rare in leukemia and related disorders, this diagnosis should be taken in account also when clinical symptoms are mild. Following immediate operative management, patients may completely recover and receive cytotoxic chemotherapy with substantial possibilities of achieving complete remission.

Published
1998

49. Combined CD133/CD44 expression as a prognostic indicator of disease-free survival in patients with colorectal cancer.

Author

Galizia G, Gemei M, Del Vecchio L, Zamboli A, Di Noto R, Mirabelli P, Salvatore F, Castellano P, Orditura M, De Vita F, Pinto M, Pignatelli C, and Lieto E

Abstract

Hypothesis: Because of some inconsistencies in the traditional model of human colorectal carcinogenesis, the cancer stem cell (CSC) model was recently proposed, in which tumor results from neoplastic transformation of stem cells, which become CSCs. Identification of CSCs by expression of surface antigens remains a critical issue because no biomarker has been shown to be completely reliable. CD133 and CD44 are commonly used as CSC markers, and correlation of their expression with colorectal cancer (CRC) clinicopathological features and outcomes may be useful. Design: Pilot study. Setting: University hospital. Patients: Thirty-six consecutive patients with CRC. CD133 and CD44 expression (alone or combined) was determined in nontumor cells and in tumor cells by flow cytometry, which identified viable cells only. Main Outcome Measures: Correlation of CD133 and CD44 expression with each other, with other prognostic indicators, and with disease-free survival. Results: CD133 and CD44 expression was significantly higher in tumor cells than in nontumor cells, and expression of one did not necessarily correlate with expression of the other. CD133 or CD44 expression alone was variable, while combined CD133/CD44 expression identified a small subset of cells positive for CRC. CD133 or CD44 overexpression was not associated with CRC recurrence; only high frequencies of CD133+/CD44+ cells were a strong indicator of worse disease-free survival and an independent risk factor for CRC recurrence. Conclusion: Evaluation of combined CD133/CD44 expression could be useful to identify putative colorectal CSCs and tumors with a poor prognosis. [ABSTRACT FROM AUTHOR]

Published
2012

50. Polychromatic flow cytometry analysis of CD34+ hematopoietic stem cells in cryopreserved early preterm human cord blood samples.

Author

D'Alessio, F., Mirabelli, P., Gorrese, M., Scalia, G., Gemei, M., Mariotti, E., Di Noto, R., Martinelli, P., Fortunato, G., Paladini, D., and Del Vecchio, L.

Abstract

During the last decades, extended characterizations were performed of human full-term cord blood (hTCB) cells, but little information is available on human early preterm cord blood (hEPCB) hematopoietic stem cells (HSCs). In our study, we analyzed by flow cytometry 19 hEPCB and 17 hTCB samples. First, we observed that the percentage of CD34PosCD45Dim cells was higher in hEPCB compared with hTCB and that it decreased during 16th-20th week of pregnancy. Within the CD34PosCD45Dim population, we examined the expression of CD29, CD31, CD38, CD90, CD117, CD133, CD135, CD200, CD243, and CD338. We found that CD135 intensity and CD243Pos cells percentage were lower in hEPCB compared with hTCB. As to CD38, we observed that hEPCB samples were richer in undifferentiated CD34PosCD45DimCD38Neg HSCs compared with hTCB counterparts. We also compared the expression of the above-mentioned molecules in undifferentiated and committed HSCs residing in hEPCB and hTCB. In particular, although CD34PosCD45DimCD38Pos HSCs from both hEPCB and hTCB expressed relatively higher amounts of CD29, CD71, and CD135 compared with CD34PosCD45DimCD38Neg cells, a higher expression of CD31 was restricted to CD34PosCD45DimCD38Pos cells from hEPCB samples, and a higher expression of CD117 was demonstrated in CD34PosCD45DimCD38Pos cells from hTCB samples. Moreover, our data showed that CD34PosCD45Dim cell population from hEPCB displayed higher percent of undifferentiated CD38NegCD133Pos cells compared with hTCB samples. Finally, analyzing monocytes and lymphocytes within the two samples, we observed that T-cell percentages were higher in hTCB, whereas B-cell percentages were higher in hEPCB. We, therefore, studied the B-cell lineage maturation and found a higher percent of pro-B and pre-B cells in hEPCB compared with hTCB samples. Taken together, these results evidence the hematopoietic peculiarity of hEPCB, potentially useful for highlighting early steps of human hematolymphopoiesis as well as for developing novel strategies of stem cell-based therapy. © 2010 International Society for Advancement of Cytometry [ABSTRACT FROM AUTHOR]

Published
2011
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results